Patent · US Active

DAC HYP compositions and methods

US9260528B2 · kind B2 · utility

6Cited by
1References
8Claims
0Family size

Assignee

Inventors

Key dates

Filing dateJun 9, 2015
Grant dateFeb 16, 2016
Priority date—
Expiry dateJun 9, 2035

Classification

  • Technology area (CPC Y)Emerging Cross-Sectional Technologies
  • CPC primaryY02A50/30
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

The present disclosure relates to compositions of daclizumab suitable for subcutaneous administration and methods of manufacturing thereof.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.